Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE008 (KOR) (Dr. Kim)
· consented 2022-08-05
Adverse events
5
Serious AEs
0
Open data queries
0
Luna dropout signal
–
Adverse events
severe
assessed
2026-08-18
Grade 3 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-01-01 (study day 139); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-01-13 (study day 151); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-02-18 (study day 187); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-02-20 (study day 189); relationship: N
mild
assessed
2026-08-18
Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-04-06 (study day 234); relationship: not assessed
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.